Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAU868 for prevention of BKV infection in kidney transplant
NCT03456999Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in BK virus infection comparing MAU868 with Placebo (2 arms). Primary endpoint: Incidence of BK viremia at 24 weeks. Planned start Oct 2018; status: withdrawn.
02
Drugs
traxivitug
03
Conditions
BK virus infection
Beyond the preview
Go deeper on NCT03456999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456999.